用于呼吸道合胞病毒预防的帕利珠单抗：经验教训与新视野战略

Reports on Global Health Research Pub Date : 2023-11-24 DOI:10.29011/2690-9480.100177

Giamberardino Hig, JM Webler, Giamberardino Alg, LA Pereira, SM Raboni

{"title":"用于呼吸道合胞病毒预防的帕利珠单抗：经验教训与新视野战略","authors":"Giamberardino Hig, JM Webler, Giamberardino Alg, LA Pereira, SM Raboni","doi":"10.29011/2690-9480.100177","DOIUrl":null,"url":null,"abstract":"Background: The monoclonal antibody Palivizumab (PVZ) has been used for 25 years to prevent Respiratory Syncytial Virus (RSV) infections. Evidence regarding its performance in low and middle-income countries (LMIC) is scarce. In this uniquely conducted study in Brazil, we showed the real-life use of PVZ in a public health context","PeriodicalId":281954,"journal":{"name":"Reports on Global Health Research","volume":"643 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Palivizumab for Respiratory Syncytial Virus Prophylaxis: Lessons Learned and Strategies for New Horizons\",\"authors\":\"Giamberardino Hig, JM Webler, Giamberardino Alg, LA Pereira, SM Raboni\",\"doi\":\"10.29011/2690-9480.100177\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The monoclonal antibody Palivizumab (PVZ) has been used for 25 years to prevent Respiratory Syncytial Virus (RSV) infections. Evidence regarding its performance in low and middle-income countries (LMIC) is scarce. In this uniquely conducted study in Brazil, we showed the real-life use of PVZ in a public health context\",\"PeriodicalId\":281954,\"journal\":{\"name\":\"Reports on Global Health Research\",\"volume\":\"643 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reports on Global Health Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29011/2690-9480.100177\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports on Global Health Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29011/2690-9480.100177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景：单克隆抗体帕利珠单抗（PVZ）用于预防呼吸道合胞病毒（RSV）感染已有 25 年之久。有关其在中低收入国家（LMIC）的表现的证据却很少。在这项在巴西进行的独特研究中，我们展示了 PVZ 在公共卫生领域的实际应用情况

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Palivizumab for Respiratory Syncytial Virus Prophylaxis: Lessons Learned and Strategies for New Horizons

Background: The monoclonal antibody Palivizumab (PVZ) has been used for 25 years to prevent Respiratory Syncytial Virus (RSV) infections. Evidence regarding its performance in low and middle-income countries (LMIC) is scarce. In this uniquely conducted study in Brazil, we showed the real-life use of PVZ in a public health context

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Reports on Global Health Research

自引率

0.00%

发文量